Search
Tuesday 9 June 2015
  • :
  • :
Latest Update

Volume Active Stocks Under Consideration: American Capital (NASDAQ:ACAS), Revance Therapeutics (NASDAQ:RVNC), Pepco Holdings, (NYSE:POM), Akamai Technologies, (NASDAQ:AKAM)

On Wednesday, American Capital Ltd. (NASDAQ:ACAS)’s shares inclined 0.07% to $14.27.

American Capital Ltd. (ACAS) declared that it acted as sole lender and second lien agent on a $51 million second lien financing to support the acquisition of Compusearch Software Systems, Inc. (“Compusearch”) by ABRY Partners. Compusearch is the leading provider of acquisition and program administration software to federal agencies, Department of Defense program offices and government contractors.

Headquartered in Dulles, VA, Compusearch provides software and services that advance commerce and partnershipamong government agencies and contractors. Compusearch’s PRISM™ software is fully compliant with Federal Acquisition Regulations and is the contract writing system for defense, intelligence and civilian agencies. PRISM™ automates requisition and solicitation generation, competitive bid evaluation, award generation, contract administration, administration reporting, and contract closeout and archiving, and also significantly speeds up compliance with the complex bidding rules for federal contracts. Compusearch’s software solutions also comprise TopVue™ for program execution and deliverable support and SpectrumCLM™ for Government Contractor’s Contract Lifecycle Administration (CLM) processes.

American Capital, Ltd. is a private equity and venture capital firm specializing in administration and employee buyouts, subordinated debt, leveraged finance, mezzanine, acquisition, recapitalization, middle market, early venture, mature, industry consolidation, and growth capital investments.

Revance Therapeutics Inc (NASDAQ:RVNC)’s shares gained 18.43% to $30.72.

Revance Therapeutics Inc (RVNC) planned to present at the William Blair 2015 Growth Stock Conference in Chicago on Wednesday, June 10 at 12:00pm CDT.

Revance Therapeutics, Inc., a clinical-stage specialty biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications.

At the end of Wednesday’s trade, Pepco Holdings, Inc. (NYSE:POM)‘s shares surged 0.04% to $27.05.

The Delaware Public Service Commission (PSC) issued an order approving the merger between Exelon Corporation (EXC) and Pepco Holdings Inc. (POM) upon the terms set forth in the parties’ application, as amended by the Amended Settlement Agreement filed with the PSC on April 7, 2015. This action follows the Commission’s deliberations on May 19, 2015, when the Commission voted to approve the Amended Settlement Agreement. Recently’s order approves the merger and authorizes the consummation of the merger. A further order with the PSC’s specific grounds for approval will follow at a later date. The companies declared their projected merger on April 30, 2014, and presented their application to merge to the PSC on June 18, 2014.

The Amended Settlement Agreement was filed by Exelon, PHI and Delmarva Power on April 7, 2015, and signed by PSC Staff, the Delaware Public Advocate, the Department of Natural Resources and Environmental Control (DNREC), the Delaware Sustainable Energy Utility, the Mid-Atlantic Renewable Energy Coalition and the Clean Air Council. The terms provide more than $42 million in direct benefits, deliver noteworthyeconomic benefits to Delaware and Delmarva Power customers, promote energy efficiency, enhance reliability, support workforce development and promote the public interest.

Pepco Holdings, Inc., through its auxiliaries, engages in the transmission, distribution, and supply of electricity. The company also distributes and supplies natural gas. In addition, the company designs, constructs, and operates energy projects and distributed generation equipment, counting combined heat and power plants principally for federal, state, and local government customers.

Akamai Technologies, Inc. (NASDAQ:AKAM), ended its Wednesday’s trading session with 0.74% gain, and closed at $76.02.

Akamai Technologies, Inc. (AKAM) declared a new planned alliance designed to assist businesses more effectively fight a wide range of malicious online activities through vulnerability assessment, denial of service prevention and incident response.

Through this partnership, Akamai and Trustwave plan to make accessible to their respective customers select technology solutions and security services from each company’s portfolio. The planned relationship is intended to allow both companies to provide a broader set of cyber security protections to meet a wide range of customer requirements in a constantly changing cyber security threat landscape.

Akamai Technologies, Inc. provides cloud services for delivering, optimizing, and securing online content and business applications in the United States and internationally.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.




Leave a Reply

Your email address will not be published. Required fields are marked *